Triple
T1143216
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | European Medicines Agency |
E23502
|
entity |
| Predicate | hasCommittee |
P1396
|
FINISHED |
| Object |
Pharmacovigilance Risk Assessment Committee
The Pharmacovigilance Risk Assessment Committee is a scientific body responsible for evaluating and monitoring the safety of human medicines and advising on risk management measures in the European Union.
|
E130558
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Pharmacovigilance Risk Assessment Committee | Statement: [European Medicines Agency, hasCommittee, Pharmacovigilance Risk Assessment Committee]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Pharmacovigilance Risk Assessment Committee Context triple: [European Medicines Agency, hasCommittee, Pharmacovigilance Risk Assessment Committee]
-
A.
Committee for Proprietary Medicinal Products
The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
-
B.
Committee for Medicinal Products for Veterinary Use
The Committee for Medicinal Products for Veterinary Use is the European Medicines Agency’s scientific committee responsible for evaluating and providing opinions on veterinary medicines in the European Union.
-
C.
Committee for Herbal Medicinal Products
The Committee for Herbal Medicinal Products is a scientific body within the European Medicines Agency that evaluates and provides guidance on the safety and efficacy of herbal medicines in the European Union.
-
D.
Committee for Orphan Medicinal Products
The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
-
E.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is a global body that develops and promotes unified scientific and technical standards to ensure the safety, quality, and efficacy of medicines worldwide.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Pharmacovigilance Risk Assessment Committee Triple: [European Medicines Agency, hasCommittee, Pharmacovigilance Risk Assessment Committee]
Generated description
The Pharmacovigilance Risk Assessment Committee is a scientific body responsible for evaluating and monitoring the safety of human medicines and advising on risk management measures in the European Union.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Pharmacovigilance Risk Assessment Committee Target entity description: The Pharmacovigilance Risk Assessment Committee is a scientific body responsible for evaluating and monitoring the safety of human medicines and advising on risk management measures in the European Union.
-
A.
Committee for Proprietary Medicinal Products
The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
-
B.
Committee for Medicinal Products for Veterinary Use
The Committee for Medicinal Products for Veterinary Use is the European Medicines Agency’s scientific committee responsible for evaluating and providing opinions on veterinary medicines in the European Union.
-
C.
Committee for Herbal Medicinal Products
The Committee for Herbal Medicinal Products is a scientific body within the European Medicines Agency that evaluates and provides guidance on the safety and efficacy of herbal medicines in the European Union.
-
D.
Committee for Orphan Medicinal Products
The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
-
E.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is a global body that develops and promotes unified scientific and technical standards to ensure the safety, quality, and efficacy of medicines worldwide.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69a493ef399c8190b04b9146d2314f59 |
completed | March 1, 2026, 7:30 p.m. |
| NER | Named-entity recognition | batch_69a4bc4e93d48190b9fea886bf61aad7 |
completed | March 1, 2026, 10:23 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69ac59b2395c81909d4608bdaf1d57e8 |
completed | March 7, 2026, 5 p.m. |
| NEDg | Description generation | batch_69ac5b52c43c8190b8972826a9a1ea5f |
completed | March 7, 2026, 5:07 p.m. |
| NED2 | Entity disambiguation (via description) | batch_69ac5be4d9548190a0f1d57538f688c1 |
completed | March 7, 2026, 5:09 p.m. |
Created at: March 1, 2026, 7:44 p.m.